HRIPT Study to Evaluate the Irritation and Allergenic Potential of Medical-grade Norway Spruce (Picea Abies) Resin Salve (Abilar)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

215 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-16

Study Completion Date

2019-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to assess whether a medical-grade Norway spruce resin-based topical product (Abilar) causes skin irritation or allergic sensitization in healthy adult volunteers. The main questions it aims to answer are:

Does the product cause skin irritation after repeated applications? Does the product induce sensitization (allergic contact dermatitis) after repeated exposure?

Participants will:

Have the test product applied to their skin via occlusive patches multiple times over three weeks.

Undergo dermatological assessments for signs of erythema (redness), swelling, or sensitization at scheduled time points.

Have a final challenge application on a new skin site after a rest period to check for delayed allergic reactions.

This study follows Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki. It was conducted at Princeton Consumer Research (PCR Corp, UK) with approval from the East Anglia Ethics Committee, UK.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Skin Safety Testing of 6 Mitopure Topical Products Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers

NCT07100912

Irritation/Irritant Sensitisation

COMPLETED NA

Human Skin Safety Testing of Mitopure Topical Products Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers

NCT06884215

Irritation/Irritant Sensitisation

COMPLETED NA

Human Skin Safety Testing of a Mitopure Topical Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers

NCT05079607

Irritation/Irritant Sensitisation

COMPLETED NA

Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100

NCT03450070

Allergic Sensitization

COMPLETED NA

21 Day Cumulative Skin Irritation of RUT058-60

NCT02198963

Irritation/Irritant

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Objective:

This is a single-center, interventional study designed to evaluate the irritation and sensitization potential of a medical-grade Norway spruce resin-based wound care product (Abilar) using a Modified Draize Human Repeat Insult Patch Test (HRIPT). The study followed Good Clinical Practice (ICH GCP 1996) and the Declaration of Helsinki.

Study Design:

A total of 215 healthy adult volunteers were enrolled, with 207 completing the study. The study was conducted at Princeton Consumer Research (PCR Corp, UK) and was approved by the East Anglia Ethics Committee, UK. Participants received occlusive patches containing the test product, applied repeatedly over a three-week induction phase. After a rest period, a challenge application was placed on a new skin site to evaluate potential delayed-type hypersensitivity reactions.

Single-center, interventional study with single-group assignment (no control group).

Conducted under dermatological supervision at Princeton Consumer Research (PCR Corp, UK).

Ethical approval was granted by the East Anglia Ethics Committee, UK. Study Period: October 16, 2019 - October 25, 2019.

Methodology:

Induction Phase (Days 1-21): Repeated application of occlusive patches with the test product to the same skin site three times per week. Skin assessments were conducted at multiple time points.

Rest Period: No patch application for approximately 14 days. Challenge Phase (Day 38): A final application was made to a naïve skin site to assess delayed hypersensitivity responses.

Scoring System: Skin reactions were graded using dermatological visual scoring for erythema, edema, and other signs of irritation or sensitization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Irritation Skin Sensitization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is a single-group interventional study in which all participants received the same topical test product applied via occlusive patches. The study was designed to evaluate skin irritation and sensitization potential using a repeat insult patch test protocol.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

This study was conducted as a single-blind HRIPT, where participants were not informed of the identity of the test article applied to their skin. However, as only one test product was used without a control or comparison group, ClinicalTrials.gov does not allow classification as "Single-Blind," and the study is categorized as "Open Label" in this registration.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Medical-Grade Norway Spruce Resin product (Abilar) Topical Safety Study

Participants received repeated applications of a Medical-Grade Norway Spruce Resin product (Abilar) topical formulation using Finn chambers on Scanpor® tape. Patches were applied to the upper back for 47 hours per application over a three-week induction phase, followed by a challenge phase to assess potential delayed hypersensitivity reactions. Skin reactions were assessed at scheduled intervals by a blinded dermatologist using a standardized scoring system.

Group Type EXPERIMENTAL

Abilar® Resin Salve

Intervention Type DEVICE

Abilar® Resin Salve is a medical-grade Norway spruce (Picea abies) resin-based topical medical device, classified as a Class IIb medical device in the EU. It is designed for wound care and skin protection, forming a moist healing barrier while exhibiting antimicrobial properties. It contains 10% of medical-grade Picea abies resin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abilar® Resin Salve

Abilar® Resin Salve is a medical-grade Norway spruce (Picea abies) resin-based topical medical device, classified as a Class IIb medical device in the EU. It is designed for wound care and skin protection, forming a moist healing barrier while exhibiting antimicrobial properties. It contains 10% of medical-grade Picea abies resin.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Abilar Abilar® 10% Resin Salve Norway Spruce Resin-Based Topical Medical Device Picea abies Resin Salve Abilar Wound Salve

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers, of either sex, aged at least 18 years.
* Completed written informed consent.

Exclusion Criteria

* Pregnancy or lactation.
* Inadequate or non-existent contraception (women of child bearing potential only).
* A current skin disease of any type apart from mild facial acne (e.g. eczema, psoriasis).
* Heavy alcohol consumption (i.e. more than 21 units per week or 8 units a day for men, more than 14 units per week or 4 units a day for women).
* Current use or history of repeated use of street drugs.
* A febrile illness lasting more than 24 hours in the six days prior to first patch application.
* Significant past medical history of hepatic, renal, cardiac, pulmonary, digestive, haematological, neurological, locomotor or psychiatric disease.
* History of asthma only if requiring regular medication or hay fever that required prescription treatment in two or more of the previous three years.
* A history of multiple drug hypersensitivity.
* Concurrent medication likely to affect the response to the test articles or confuse the results of the study.
* Known sensitivity to the test articles or their constituents including patch materials.
* Current treatment by a physician for allergy unless physician consulted by Investigator and participation approved.
* Participation in a repeat insult patch test (RIPT) or follow-up work within the last month.
* Sensitisation or questionable sensitisation in a RIPT.
* Recent immunisation (less than 10 days prior to test patch application).
* A medical history indicating atopy.

Prohibitions and Restrictions:

* No use of aspirin or non-steroidal anti-inflammatory drugs for the duration of the study.
* No use of sun beds or sun lamps and no deliberate exposure of the test sites to natural sunlight for the duration of the study.
* No immunisation from ten days prior to first patching until study completion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes